

**Supplementary table. Comparison of HIV viral load values at the different time points between the PLWH HBcAb-positive and HBcAb-negative groups of patients switched to 3TC+dolutegravir.**

	HBcAb-positive (n=34)	HBcAb-negative (n=78)	p-value
Sex ratio M/F, %F	28/6 (17.6%)	56/17 (23.3%)	0.51
Age, years	49 (35-57)	55 (52-59)	<b>0.0079</b>
Calendar year of HIV diagnosis, median (range)	2009 (2007-2015)	2004 (1997-2012)	<b>0.0046</b>
Nadir CD4+ cell/mm <sup>3</sup> , median (range)	263 (166-413)	342 (226-466)	0.11
History of therapeutic failure, n (%)	9 (26.3%)	7 (9.6%)	0.12
Pre-2DR switch triple ART composition, n (%):			<b>0.002</b>
2NRTI+PI	12 (35.3%)	5 (6.8%)	
2NRTI+NNRTI	9 (26.5%)	23 (31.5%)	
2NRTI+INI	12 (35.3%)	42 (57.5%)	
Other	1 (2.9%)	3 (4.1%)	
CD4+ cell/mm <sup>3</sup> at 2DR switch, median (range)	781 (565-982)	756 (558-952)	<b>0.029</b>
HIV RNA 24 months pre-2DR switch, n (%):			0.89
pts <20 copies/ml	26 (76.5%)	55 (75.3%)	
pts <20 copies/ml target detected	8 (23.5%)	18 (24.6%)	
HIV RNA 12 months pre-2DR switch, n (%):			0.18
pts <20 copies/ml	23 (67.6%)	58 (79.4%)	
pts <20 copies/ml target detected	11 (32.3%)	15 (20.5%)	
HIV RNA at 2DR switch, n (%):			0.63
pts <20 copies/ml	26 (76.5%)	55 (75.3%)	
pts <20 copies/ml target detected	7 (20.6%)	17 (23.3%)	
Not available	1 (3%)	1 (1.4%)	
HIV RNA 6 months post-2DR switch, n (%):			0.12
pts <20 copies/ml	24 (70.6%)	61 (83.6%)	
pts <20 copies/ml target detected	10 (29.4%)	12 (16.4%)	
HIV RNA 12 months post-2DR switch, n (%)*:			<b>0.02</b>
pts <20 copies/ml	10 (32.3%)	37 (63.8%)	
pts <20 copies/ml target detected	11 (35.4%)	14 (24.1%)	
pts detectable >20 copies/ml	10 (32.3%)	7 (12.1%)	
HIV RNA 24 months post-2DR switch, n (%)**:			<b>0.006</b>
pts <20 copies/ml	5 (20.8%)	26 (54.2%)	
pts <20 copies/ml target detected	9 (37.5%)	16 (33.3%)	
pts detectable >20 copies/ml	10 (41.7%)	6 (12.5%)	

Abbreviations: 3TC: lamivudine; NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: nonnucleoside reverse transcriptase inhibitors; PI: protease inhibitors; DTG: dolutegravir; 2DR: two-drug antiretroviral therapy; pts: patients; HBcAb-positive: patients with antibodies against hepatitis B c antigen \* Data available for 81 pts; \*\* Data available for 72 pts